Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when STTK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsShattuck Labs raises in dilutive public offering, sells 10.9M shares and 7.9M warrants
Filed June 11, 2026 · Period ending June 9, 2026 · ~1 min read
Key Changes
-
high
Company sold 10.9M common shares at $4.00 and 7.9M pre-funded warrants at $3.9999, raising $0.0001 before fees. This represents significant dilution to existing shareholders.
Item 1.01 verify on EDGAR → -
medium
Underwriters exercised full over-allotment option for additional 2.8M shares on June 10, increasing total offering size by 15% and signaling strong investor demand.
Item 1.01 verify on EDGAR → -
medium
Pre-funded warrants are immediately exercisable at $0.0001 per share with ownership caps at 4.99% or 9.99%, making them economically equivalent to common stock and likely to be exercised promptly.
Item 1.01 verify on EDGAR → -
low
Offering expected to close June 11, 2026, with proceeds available shortly after filing date.
Item 1.01 verify on EDGAR →
Summary
Shattuck Labs completed a substantial capital raise through an underwritten public offering, selling nearly 11 million common shares and 8 million pre-funded warrants at approximately $4.00 per unit. The offering, led by four major investment banks including Leerink Partners and J.P. Morgan, will inject roughly into the company before underwriting fees.
The full exercise of the over-allotment option suggests institutional investors view the pricing favorably. For existing shareholders, this represents meaningful dilution—the combined 21.6 million shares and warrants will significantly increase the outstanding share count.
The pre-funded warrants, priced at $3.9999 with a nominal $0.0001 exercise price, are essentially common stock equivalents that holders will likely exercise immediately, making the dilution immediate rather than potential. Investors should watch for the company's use of proceeds disclosure in the related prospectus supplement and monitor cash burn rates in upcoming quarterly reports. The capital raise suggests the company needed runway, so tracking how long these funds last and whether clinical milestones are achieved before another financing becomes necessary will be critical.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Shattuck Labs completed an underwritten public offering with pre-funded warrants on June 9, 2026.
Added in current filing · verify on EDGAR →
Underwriting Agreement, dated as of June 9, 2026, by and among Shattuck Labs, Inc., Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co.
Shattuck Labs entered into an underwriting agreement on June 9, 2026 with four investment banks (Leerink Partners, J.P. Morgan Securities, Piper Sandler, and Cantor Fitzgerald) to conduct a public offering. The inclusion of pre-funded warrants suggests the company is raising capital through a combination of common stock and warrant instruments.
Added in current filing · verify on EDGAR →
Form of Pre-Funded Warrant
The company issued pre-funded warrants as part of this offering. Pre-funded warrants are typically used in biotech offerings to provide investors with near-equity exposure at a minimal exercise price, often resulting in immediate or near-term dilution to existing shareholders.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 11, 2026 · How we verify